<DOC>
	<DOCNO>NCT00982228</DOCNO>
	<brief_summary>This trial conduct Africa , Europe United States America ( USA ) . The aim trial compare NN1250 ( insulin degludec , soluble insulin basal analogue ( SIBA ) ) plus insulin aspart insulin glargine ( IGlar ) plus insulin aspart patient type 1 diabetes . The main period register internally Novo Nordisk NN1250-3583 extension period register NN1250-3644 .</brief_summary>
	<brief_title>Comparison NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 1 diabetes mellitus least 12 month Current treatment basal bolus insulin least 12 month HbA1c equal 10.0 % BMI ( Body Mass Index ) equal 35.0 kg/m^2 For extension trial : Completion 52 week treatment period trial NN12503583 ( NCT00982228 ) Use antidiabetic drug insulin within last 3 month Cardiovascular disease within last 6 month Uncontrolled treated/untreated severe hypertension Recurrent severe hypoglycemia hypoglycemic unawareness hospitalisation diabetic ketoacidosis previous 6 month Pregnancy , breastfeeding , intention become pregnant use adequate contraceptive measure accord local requirement Cancer medical history cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>